Chicago, ILNCT06055439Now EnrollingIRB Ready

I cannot determine the primary medical condition from the provided information. The study title mentions CAR-T cell therapy targeting Cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. The brief summary appears to be incomplete (showing only a localhost URL). Without additional context about what cancer or condition this CAR-T therapy is intended to treat, I cannot provide the patient-facing medical condition. Clinical Trial in Chicago, IL

Access cutting-edge i cannot determine the primary medical condition from the provided information. the study title mentions car-t cell therapy targeting cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. the brief summary appears to be incomplete (showing only a localhost url). without additional context about what cancer or condition this car-t therapy is intended to treat, i cannot provide the patient-facing medical condition. treatment through this phase 1/2 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Chimeric Therapeutics

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access i cannot determine the primary medical condition from the provided information. the study title mentions car-t cell therapy targeting cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. the brief summary appears to be incomplete (showing only a localhost url). without additional context about what cancer or condition this car-t therapy is intended to treat, i cannot provide the patient-facing medical condition. specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related i cannot determine the primary medical condition from the provided information. the study title mentions car-t cell therapy targeting cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. the brief summary appears to be incomplete (showing only a localhost url). without additional context about what cancer or condition this car-t therapy is intended to treat, i cannot provide the patient-facing medical condition. treatment provided free

Apply for This Chicago Location

Check if you qualify for this i cannot determine the primary medical condition from the provided information. the study title mentions car-t cell therapy targeting cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. the brief summary appears to be incomplete (showing only a localhost url). without additional context about what cancer or condition this car-t therapy is intended to treat, i cannot provide the patient-facing medical condition. clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This I cannot determine the primary medical condition from the provided information. The study title mentions CAR-T cell therapy targeting Cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. The brief summary appears to be incomplete (showing only a localhost URL). Without additional context about what cancer or condition this CAR-T therapy is intended to treat, I cannot provide the patient-facing medical condition. Study in Chicago

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

Sponsor: Chimeric Therapeutics

Who Can Participate

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative.
Confirmed histologic diagnosis of one of the following solid tumors of GI origin:
Gastric adenocarcinoma Note: for gastric adenocarcinoma patients only, central laboratory confirmation of CDH17+ tumor expression is required.
Colon and/or rectal adenocarcinoma
G1, G2, and well-differentiated G3 neuroendocrine tumors of the midgut and hindgut (ileal, jejunal, cecal, distal colonic, or rectal; with ≤ 55% Ki67 expression)
Availability of unstained tumor tissue slides from archived tumor tissue or a new tumor biopsy, if medically feasible. Note: for gastric adenocarcinoma patients only, confirmation of CDH17+ is required prior to study inclusion.
Have received at least 1 prior line of systemic anti-cancer treatment in the locally advanced or metastatic setting, as defined by National Comprehensive Cancer Network (NCCN) guidelines. Participants must have received or declined FDA-approved and available treatment options, including targeted therapies for disease mutation or antigen expression status.
Age ≥ 18 years and ≤ 85 years.
For Phase 1 Dose Expansion and Phase 2 only: Measurable disease as per RECIST v1.1 criteria (Note: Measurable disease is NOT required for Phase 1 Dose Escalation).
Eastern Cooperative Oncology Group (ECOG) ≤ 1.
Life expectancy ≥ 12 weeks.
No known contraindications to leukapheresis, cyclophosphamide, fludarabine, or steroids.
Baseline laboratory values as shown in the following table: Minimum Laboratory Values for Study Entry Laboratory Assessment Criteria White blood cell count \> 4,000/mm3 Absolute neutrophil count (ANC) ≥ 1,500/mm3 Platelets ≥ 100,000/mm3 Hemoglobin ≥ 10 g/dL Total bilirubin ≤ 1.5 x upper limit of normal (ULN) Aspartate amino transferase (AST) ≤ 3 x ULN Alanine transaminase (ALT) ≤ 3 x ULN Creatinine clearance by Cockroft-Gault equation 60 mL/min Oxygen saturation ≥ 92% on room air Albumin ≥ 3 g/dL
Left ventricular ejection fraction ≥ 50%.
Seronegative for human immunodeficiency virus (HIV) by antigen/antibody (Ag/Ab) testing.
Seronegative for hepatitis B and/or hepatitis C virus.
Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
Agreement by women and men of childbearing potential to use an effective method of birth control or abstain from heterosexual activity through at least 3 months after the last dose of CHM-2101.

Exclusion Criteria

Previous treatment with CDH17-targeted therapies.
Unresolved toxicities from prior therapy except for chronic toxicity no greater than Grade 1 and stable \> 30 days (Note: alopecia of any grade is not exclusionary).
Uncontrolled seizure activity and/or known central nervous system (CNS) metastases.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
Uncontrolled Crohn's disease, ulcerative colitis, or other autoimmune or inflammatory disorders of the GI tract. "Uncontrolled" is defined as requiring hospitalization, corticosteroids, or chronic medication increase (dosage or frequency) within the previous 6 months.
Liver involvement ≥ 50%.
Active infection requiring oral or IV antibiotics.
Current diagnosis of pleural effusions, interstitial lung disease, or heart failure of New York Heart Association Classification of Heart Failure Class III or IV.
Ongoing treatment with systemic corticosteroid therapy at doses of prednisone ≥ 20 mg/day or equivalent (lower doses of corticosteroid therapy are allowed until 7 days prior to leukapheresis).
No prior malignancy within 5 years except for non-melanomatous skin cancer or cervical cancer treated with curative intent
Currently breastfeeding or planning to become pregnant within 9 months of study enrollment.
Any other clinically significant uncontrolled illness or other comorbid condition that would, in the investigator's judgment, contraindicate the participant's participation in the clinical study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06055439) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

I cannot determine the primary medical condition from the provided information. The study title mentions CAR-T cell therapy targeting Cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. The brief summary appears to be incomplete (showing only a localhost URL). Without additional context about what cancer or condition this CAR-T therapy is intended to treat, I cannot provide the patient-facing medical condition. Treatment Options in Chicago, IL

If you're searching for i cannot determine the primary medical condition from the provided information. the study title mentions car-t cell therapy targeting cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. the brief summary appears to be incomplete (showing only a localhost url). without additional context about what cancer or condition this car-t therapy is intended to treat, i cannot provide the patient-facing medical condition. treatment options in Chicago, IL, this clinical trial (NCT06055439) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced i cannot determine the primary medical condition from the provided information. the study title mentions car-t cell therapy targeting cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. the brief summary appears to be incomplete (showing only a localhost url). without additional context about what cancer or condition this car-t therapy is intended to treat, i cannot provide the patient-facing medical condition. specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all i cannot determine the primary medical condition from the provided information. the study title mentions car-t cell therapy targeting cadherin 17, but the conditions section only lists the treatment itself rather than the disease being treated. the brief summary appears to be incomplete (showing only a localhost url). without additional context about what cancer or condition this car-t therapy is intended to treat, i cannot provide the patient-facing medical condition. clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Chicago, IL

See all multiple myeloma clinical trials recruiting in Chicago — not just this study.

Browse Multiple Myeloma Trials in Chicago →

Browse More Trials by Condition

Multiple Myeloma TrialsHeart Disease TrialsHeart Attack TrialsPulmonary Embolism TrialsAlzheimers Disease TrialsEssential Tremor TrialsADHD TrialsRheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL